Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities

References

• Kruger S, Ilmer M, Kobold S, et al. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019;38(1):268.
   PubMed Web of Science ®Google Scholar
• Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–129.
   PubMed Web of Science ®Google Scholar
• Nurgali K, Jagoe RT, Abalo R. Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018;9:245.
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104.
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Munn LL, Jain RK. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. Trends Cancer. 2018;4(4):292–319.
   PubMed Web of Science ®Google Scholar
• Kosmidis C, Sardeli C, Zaragoulidis P, et al. Producing the appropriate model and drug for intratumoural ablation. Br J Cancer, 2020
   Google Scholar
• Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159(1):14–26.
   PubMed Web of Science ®Google Scholar
• Celikoglu F, Celikoglu SI, Goldberg EP. Techniques for intratumoral chemotherapy of lung cancer by bronchoscopic drug delivery. Cancer Ther. 2008;6:545–552.
   Google Scholar
• Fakhari A, Anand Subramony J. Engineered in-situ depot-forming hydrogels for intratumoral drug delivery. J Control Release. 2015;220(Pt A):465–475.
   PubMed Web of Science ®Google Scholar
• Goldberg EP, Hadba AR, Almond BA, et al. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol. 2002;54(2):159–180.
   PubMed Web of Science ®Google Scholar
• Budker VG, Monahan SD, Subbotin VM. Loco-regional cancer drug therapy: present approaches and rapidly reversible hydrophobization (RRH) of therapeutic agents as the future direction. Drug Discov Today. 2014;19(12):1855–1870.
   PubMed Web of Science ®Google Scholar
• Garrastazu Pereira G, Lawson AJ, Buttini F, et al. Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Deliv. 2016;23(8):2881–2896.
   PubMed Web of Science ®Google Scholar
• REESE AB, et al. The treatment of retinoblastoma by X-Ray and triethylene melamine. JAMA Ophthalmol. 1958;60(5):897–906.
   Google Scholar
• Kiribuchi M. [Retrograde infusion of anti-cancer drugs to ophthalmic artery for intraocular malignant tumors]. Nippon Ganka Gakkai Zasshi. 1966;70(11):1829–1833.
   PubMedGoogle Scholar
• Abramson DH, Shields CL, Jabbour P, et al. Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide. Int J Retina Vitreous. 2017;3(1):40.
   PubMedGoogle Scholar
• Chen Q, Zhang B, Dong Y, et al. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. BMC Cancer. 2018;18(1):486.
   PubMedGoogle Scholar
• Yousef YA, Soliman SE, Astudillo PPP, et al. Intra-arterial chemotherapy for retinoblastoma: a systematic review. JAMA Ophthalmol. 2016;134(5):584–591.
   PubMed Web of Science ®Google Scholar
• Ceresoli M, Frigerio L, Ansaloni L. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378(14):1363.
   PubMedGoogle Scholar
• Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104(6):692–698.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev. 2016;48:42–49.
   PubMed Web of Science ®Google Scholar
• Deraco M, Kusamura S, Virzì S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215–220.
   PubMed Web of Science ®Google Scholar
• Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113(2):315–325.
   PubMed Web of Science ®Google Scholar
• Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18(12):1943–1950.
   PubMed Web of Science ®Google Scholar
• Ceelen W, Braet H, van Ramshorst G, et al. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion. Expert Opin Drug Deliv. 2020;17(4):511–522.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2(2):68–75.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhu Y, Liu C, et al. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis. J Ovarian Res. 2019;12(1):33.
   PubMedGoogle Scholar
• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–1466.
   PubMed Web of Science ®Google Scholar
• Mehta SS, Gelli M, Agarwal D, et al. Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian J Surg Oncol. 2016;7(2):225–229.
   PubMed Web of Science ®Google Scholar
• Ohto M, Ebara M, Kita K, et al. Treatment of Liver Carcinoma by Percutaneous Intratumoral Ethanol Injection. In: Henner HDeditor. Ultraschalldiagnostik ’88. Berlin, Heidelberg: Springer Berlin Heidelberg; 1989. p. 155–159.
   Google Scholar
• Lencioni R, Crocetti L, Cioni D, et al. Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study. J Vasc Interv Radiol. 2010;21(10):1533–1538.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Cioni D, Crocetti L, et al. Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl. 2004;10(Suppl S2):S91–7.
   PubMedGoogle Scholar
• Fuge O, et al. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65–79.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–1970.
   PubMed Web of Science ®Google Scholar
• Alexandroff AB, Jackson AM, O’Donnell MA, et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353(9165): 1689–1694.
   PubMed Web of Science ®Google Scholar
• Brausi M, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69–76.
   PubMed Web of Science ®Google Scholar
• Pfister C, Kerkeni W, Rigaud J, et al. Efficacy and tolerance of one-third full dose bacillus Calmette-Guerin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol. 2015;22(1):53–60.
   PubMed Web of Science ®Google Scholar
• Agarwala SS, et al. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004;100(8):1692–1698.
   PubMed Web of Science ®Google Scholar
• Abbott AM, Zager JS. Locoregional therapies in melanoma. Surg Clin North Am. 2014;94(5):1003–1015. viii.
   PubMed Web of Science ®Google Scholar
• Corbin ZA, Nagpal S. Leptomeningeal Metastases. JAMA Oncol. 2016;2(6):839.
   PubMed Web of Science ®Google Scholar
• Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treat Rev. 2017;53(p):128–137.
   PubMedGoogle Scholar
• Glantz MJ, Van Horn A, Fisher R, et al. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116(8):1947–1952.
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Preusser M, van den Bent M, et al. How we treat patients with leptomeningeal metastases. ESMO Open. 2019;4(Suppl 2):e000507.
   PubMedGoogle Scholar
• Pacira Shutters DepCyt Operations After Years of Manufacturing Problems. 2017 2020 10 16]; Available from: https://www.fdanews.com/articles/182667-pacira-shutters-depcyt-operations-after-years-of-manufacturing-problems.
   Google Scholar
• Niu Q, Wang W, Li Q, et al. Percutaneous fine-needle 5% ethanol-cisplatin intratumoral injection combined with second-line chemotherapy improves on the standard of care in patients with platinum-pretreated stage IV non-small cell lung cancer. Transl Oncol. 2014;7(2):303–308.
   PubMed Web of Science ®Google Scholar
• Celikoglu F, Celikoglu SI, Goldberg EP. Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer. 2008;61(1):1–12.
   PubMed Web of Science ®Google Scholar
• Li SY, Li Q, Guan W-J, et al. Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial. Lung Cancer. 2016;98:43–50.
   PubMed Web of Science ®Google Scholar
• Yan BM, Van Dam J. Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer. Can J Gastroenterol. 2008;22(4):405–410.
   PubMed Web of Science ®Google Scholar
• Levy MJ, Alberts SR, Bamlet WR, et al. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointest Endosc. 2017;86(1):161–169.
   PubMed Web of Science ®Google Scholar
• Roelcke U, et al. PET Imaging Drug Distribution After Intratumoral Injection: the Case for 124I-Iododeoxyuridine in Malignant Gliomas. J Nucl Med. 2002;43(11):1444–1451.
   PubMed Web of Science ®Google Scholar
• Domb AJ, Israel ZH, Elmalak O, et al. Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors. Pharm Res. 1999;16(5):762–765.
   PubMed Web of Science ®Google Scholar
• FDA. Gliadel Wafer (polifeprosan 20 with carmustine implant). 1997 2019 11 29]; Available from: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/3583-gliadel-wafer-polifeprosan-20-with-carmustine-implant.
   Google Scholar
• Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41(6):403–419.
   PubMed Web of Science ®Google Scholar
• Dang W, Daviau T, Ying P, et al. Effects of GLIADEL® wafer initial molecular weight on the erosion of wafer and release of BCNU. J Control Release. 1996;42(1):83–92.
   Web of Science ®Google Scholar
• Strasser JF, et al. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. J Pharmacol Exp Ther. 1995;275(3):1647–1655.
   PubMed Web of Science ®Google Scholar
• Fung LK, Shin M, Tyler B, et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res. 1996;13(5):671–682.
   PubMed Web of Science ®Google Scholar
• Fung LK, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 1998;58(4):672–684.
   PubMed Web of Science ®Google Scholar
• Sage W, Guilfoyle M, Luney C, et al. Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit. J Neurooncol. 2018;136(2):273–280.
   PubMed Web of Science ®Google Scholar
• De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir (Wien). 2012;154(8):1371–1378.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence, Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. Technology appraisal guidance [TA121]. 2007.
   Google Scholar
• Hart MG, et al. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 2011(3):CD007294.
   PubMed Web of Science ®Google Scholar
• Chowdhary SA, Ryken T, Newton HB. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neurooncol. 2015;122(2):367–382.
   PubMed Web of Science ®Google Scholar
• Xing WK, et al. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis. Drug Des Devel Ther. 2015;9:3341–3348.
   PubMed Web of Science ®Google Scholar
• Ashby LS, Smith KA, Stea B. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World J Surg Oncol. 2016;14(1):225.
   PubMedGoogle Scholar
• Champeaux C, Weller J. Implantation of carmustine wafers (Gliadel®) for high-grade glioma treatment. A 9-year nationwide retrospective study. J Neurooncol. 2020;147(1):159–169.
   PubMed Web of Science ®Google Scholar
• Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18(1):44.
   PubMedGoogle Scholar
• Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37(3):212–220.
   PubMed Web of Science ®Google Scholar
• Kan Z, Madoff DC. Liver anatomy: microcirculation of the liver. Semin Intervent Radiol. 2008;25(2):77–85.
   PubMedGoogle Scholar
• Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;3:CD 004787.
   Web of Science ®Google Scholar
• Osuga K, Maeda N, Higashihara H, et al. Current status of embolic agents for liver tumor embolization. Int J Clin Oncol. 2012;17(4):306–315.
   PubMed Web of Science ®Google Scholar
• Idee JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88(3):530–549.
   PubMed Web of Science ®Google Scholar
• Dorland’s. Medical Dictionary. Elsevier.
   Google Scholar
• Giunchedi P, Maestri M, Gavini E, et al. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. Expert Opin Drug Deliv. 2013;10(5): 679–690.
   PubMed Web of Science ®Google Scholar
• 2020 08 25]; NCI drug dictionary]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ethiodized-oil.
   Google Scholar
• Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6–25.
   PubMed Web of Science ®Google Scholar
• Giunchedi P, Maestri M, Gavini E, et al. Transarterial chemoembolization of hepatocellular carcinoma – agents and drugs: an overview. Part 2. Expert Opin Drug Deliv. 2013;10(6):799–810.
   PubMed Web of Science ®Google Scholar
• Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–481.
   PubMed Web of Science ®Google Scholar
• Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. Drug Deliv. 2017;24(1):1011–1017.
   PubMed Web of Science ®Google Scholar
• Karalli A, Teiler J, Haji M, et al. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scand J Gastroenterol. 2019;54(7):905–912.
   PubMed Web of Science ®Google Scholar
• Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol. 2018;24(2):161–169.
   PubMed Web of Science ®Google Scholar
• Raoul J-L, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36.
   PubMed Web of Science ®Google Scholar
• Poursaid A, Jensen MM, Huo E, et al. Polymeric materials for embolic and chemoembolic applications. J Control Release. 2016;240:414–433.
   PubMed Web of Science ®Google Scholar
• Lewis AL, Holden RR. DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. Expert Opin Drug Deliv. 2011;8(2):153–169.
   PubMed Web of Science ®Google Scholar
• Biondi M, Fusco S, Lewis AL, et al. Investigation of the mechanisms governing doxorubicin and irinotecan release from drug-eluting beads: mathematical modeling and experimental verification. J Mater Sci Mater Med. 2013;24(10):2359–2370.
   PubMed Web of Science ®Google Scholar
• Wiggermann P, Sieron D, Brosche C, et al. Transarterial chemoembolization of child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit. 2011;17(4):CR 189–95.
   Web of Science ®Google Scholar
• Delicque J, Guiu B, Boulin M, et al. Liver chemoembolization of hepatocellular carcinoma using TANDEM((R)) microspheres. Future Oncol. 2018;14(26):2761–2772.
   PubMed Web of Science ®Google Scholar
• BTG plc, BTG announces CE Mark Certification for DC Bead LUMI™, the First commercially available Radiopaque Drug-Eluting Bead. 2017: UK.
   Google Scholar
• Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21(36):10327–10335.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis. 2016;48(6):571–577.
   PubMedGoogle Scholar
• Lee E, Leon Pachter H, Sarpel U. Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol. 2012;2012:471203.
   PubMedGoogle Scholar
• Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192–198.
   PubMed Web of Science ®Google Scholar
• Heianna J, Makino W, Ariga T, et al. Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma. Eur Radiol. 2020;30(3):1525–1533.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Mekkawy AIA, Thabet DB, et al. Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases. Eur Radiol. 2019;29(4):1939–1949.
   PubMed Web of Science ®Google Scholar
• Hakim GIL, Konorty M, Jeshurun M. Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium. EP: UROGEN PHARMA LTD; 2020.
   Google Scholar
• Donin NM, Duarte S, Lenis AT, et al. Sustained-release formulation of mitomycin c to the upper urinary tract using a thermosensitive polymer: a preclinical study. Urology. 2017;99:270–277.
   PubMed Web of Science ®Google Scholar
• García FJV, Carrión NP, de la Cruz-merino L. Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: case report. Medicine (Baltimore). 2020;99(1):e18298.
   PubMed Web of Science ®Google Scholar
• Glitza IC, Phillips S, Brown C, et al. Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). J Clin Oncol. 2020;38(15_suppl):10008.
   Web of Science ®Google Scholar
• Yu S, He C, Chen X. Injectable hydrogels as unique platforms for local chemotherapeutics-based combination antitumor therapy. Macromol Biosci. 2018;18(12):e1800240.
   PubMed Web of Science ®Google Scholar
• Chew SA, Danti S. Biomaterial-based implantable devices for cancer therapy. Adv Healthc Mater. 2017;6(2):2.
   Web of Science ®Google Scholar
• Gunji S, Obama K, Matsui M, et al. A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin. Surgery. 2013;154(5):991–999.
   PubMed Web of Science ®Google Scholar
• Karavana SY, Ay Şenyiğit Z, Çalışkan Ç, et al. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation. Drug Des Devel Ther. 2018;12:1959–1975.
   PubMed Web of Science ®Google Scholar
• Grudén S, Hassan M, Axén N. Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release drug formulations. J Drug Delivery Sci Technol. 2018;46:482–489.
   Web of Science ®Google Scholar
• Tammela TL, Häggman M, Ladjevardi S, et al. An intraprostatic modified release formulation of antiandrogen 2-hydroxyflutamide for localized prostate cancer. J Urol. 2017;198(6):1333–1339.
   PubMed Web of Science ®Google Scholar
• Sjogren E, Tammela TL, Lennernäs B, et al. Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model. Mol Pharm. 2014;11(9):3097–3111.
   PubMedGoogle Scholar
• Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–e377.
   PubMed Web of Science ®Google Scholar
• Garg PK, Jara M, Alberto M, et al. The role of Pressurized IntraPeritoneal Aerosol Chemotherapy in the management of gastric cancer: A systematic review. Pleura Peritoneum. 2019;4(1):20180127.
   PubMed Web of Science ®Google Scholar
• Baltezor M, et al. Taxane particles and their use. US: CRITITECH INC; 2016.
   Google Scholar
• NanOlogy, Proprietary Production Technology.
   Google Scholar
• Williamson SK, Johnson GA, Maulhardt HA, et al. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax(R)) in patients with peritoneal malignancies. Cancer Chemother Pharmacol. 2015;75(5):1075–1087.
   PubMed Web of Science ®Google Scholar
• Verco J, Johnston W, Baltezor M, et al. Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac((R))) in a Rodent Model. J Aerosol Med Pulm Drug Deliv. 2019;32(2):99–109.
   PubMed Web of Science ®Google Scholar
• Nayak S, Mahenthiran A, Yang Y, et al. Bone morphogenetic protein 4 targeting glioma stem-like cells for malignant glioma treatment: latest advances and implications for clinical application. Cancers (Basel). 2020;12(2):516.
   Web of Science ®Google Scholar
• Harn H-J, Lin S-Z, Lin P-C, et al. Local interstitial delivery of z-butylidenephthalide by polymer wafers against malignant human gliomas. Neuro Oncol. 2011;13(6):635–648.
   PubMed Web of Science ®Google Scholar
• Tsai NM, Chen Y-L, Lee -C-C, et al. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem. 2006;99(4):1251–1262.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Smith M, García-Martínez E, Pitter MR, et al. Trial Watch: toll-like receptor agonists in cancer immunotherapy. Oncoimmunology. 2018;7(12):e1526250.
   PubMed Web of Science ®Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4(1):7.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–167.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.
   PubMed Web of Science ®Google Scholar
• Bonaventura P, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.
   PubMed Web of Science ®Google Scholar
• Alatrash G, Jakher H, Stafford PD, et al. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12(5):631–645.
   PubMed Web of Science ®Google Scholar
• Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):128.
   PubMed Web of Science ®Google Scholar
• Aznar MA, Tinari N, Rullán AJ, et al. Intratumoral delivery of immunotherapy-act locally, think globally. J Immunol. 2017;198(1):31–39.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Tselikas L, de Baere T, et al. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017;28(suppl_12): xii33–xii43.
   PubMedGoogle Scholar
• Zhang WW, Li L, Li D, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther. 2018;29(2):160–179.
   PubMed Web of Science ®Google Scholar
• Henry CJ, Ornelles DA, Mitchell LM, et al. IL-12 Produced by Dendritic Cells Augments CD8 + T Cell Activation through the Production of the Chemokines CCL1 and CCL17. J Immunol. 2008;181(12):8576–8584.
   PubMed Web of Science ®Google Scholar
• Hammerich L, Binder A, Brody JD. In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol. 2015;9(10):1966–1981.
   PubMed Web of Science ®Google Scholar
• Algazi AP, Twitty CG, Tsai KK, et al. Phase II Trial of IL-12 Plasmid Transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res. 2020;26(12):2827–2837.
   PubMed Web of Science ®Google Scholar
• Algazi A, Bhatia S, Agarwala S, et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020;31(4):532–540.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Kirkwood JM, Guarino MJ, et al. Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand. J Clin Oncol. 2011;29(15_suppl):2540.
   Web of Science ®Google Scholar
• Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med. 2019;11(505):505.
   Web of Science ®Google Scholar
• Buscail L, Bournet B, Vernejoul F, et al. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. Mol Ther. 2015;23(4):779–789.
   PubMed Web of Science ®Google Scholar
• Liang M. Oncorine, the World First Oncolytic Virus Medicine and its Update in China. Curr Cancer Drug Targets. 2018;18(2):171–176.
   PubMed Web of Science ®Google Scholar
• AMGEN, FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US. 2015.
   Google Scholar
• Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase ii study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–1667.
   PubMed Web of Science ®Google Scholar
• Oncovir. Hiltonol Science. 2020; Available from: https://www.oncovir.com/science.
   Google Scholar
• Agarwala SS, Andtbacka RHI, Rice KN, et al. Intralesional rose bengal for treatment of melanoma. J Clin Oncol. 2016;34(15_suppl):TPS9600–TPS9600.
   Web of Science ®Google Scholar
• Maker AV, Prabhakar B, Pardiwala K. The potential of intralesional rose bengal to stimulate T-cell mediated anti-tumor responses. J Clin Cell Immunol. 2015;6(4):343.
   PubMedGoogle Scholar
• Liu H, Innamarato PP, Kodumudi K, et al. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget. 2016;7(25):37893–37905.
   PubMedGoogle Scholar
• Tabet A, Jensen MP, Parkins CC, et al. Designing next-generation local drug delivery vehicles for glioblastoma adjuvant chemotherapy: lessons from the clinic. Adv Healthc Mater. 2019;8(3):1801391.
   Web of Science ®Google Scholar
• Seo Y-E, Suh H-W, Bahal R, et al. Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials. 2019;201:87–98.
   PubMed Web of Science ®Google Scholar
• Seo YE, Bu T, Saltzman WM. Nanomaterials for convection-enhanced delivery of agents to treat brain tumors. Curr Opin Biomed Eng. 2017;4:1–12.
   PubMedGoogle Scholar
• Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518(7537):107–110.
   PubMed Web of Science ®Google Scholar
• Sayour EJ, Grippin A, De Leon G, et al. Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy. Nano Lett. 2018;18(10):6195–6206.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Wright J, Shirley S, et al. Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy. Gene Ther. 2019;26(1–2):1–15.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Milling L, Zhang Y, Irvine DJ, Delivering safer immunotherapies for cancer. Advanced Drug Delivery Reviews, 2017. 114: p. 79–101.
   Google Scholar